Global Blood Therapeutics, Inc. (NASDAQ:GBT) posted its earnings results on Monday. The company reported ($0.55) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.06, Briefing.com reports. During the same quarter last year, the company earned ($0.58) EPS.

Shares of Global Blood Therapeutics (GBT) traded down 2.04% during midday trading on Monday, hitting $28.85. The stock had a trading volume of 652,192 shares. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $41.15. The company’s 50 day moving average price is $28.28 and its 200-day moving average price is $28.34. The firm’s market capitalization is $1.26 billion.

In related news, insider Jung Choi sold 3,000 shares of the company’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $30.00, for a total value of $90,000.00. Following the transaction, the insider now owns 143,255 shares in the company, valued at approximately $4,297,650. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Deval L. Patrick sold 27,053 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total transaction of $803,203.57. Following the completion of the transaction, the director now owns 12,053 shares in the company, valued at approximately $357,853.57. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/07/global-blood-therapeutics-inc-nasdaqgbt-announces-quarterly-earnings-results.html.

Several equities analysts have commented on the stock. BidaskClub raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Oppenheimer Holdings, Inc. assumed coverage on shares of Global Blood Therapeutics in a research report on Friday. They set an “outperform” rating and a $53.00 target price on the stock. ValuEngine raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Janney Montgomery Scott assumed coverage on shares of Global Blood Therapeutics in a research report on Monday, May 1st. They set a “buy” rating and a $37.00 target price on the stock. Finally, Morgan Stanley reissued an “overweight” rating on shares of Global Blood Therapeutics in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the stock. Global Blood Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $50.59.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Earnings History for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.